Talecris signs definitive merger agreement with CSL
Closing of the transaction is subject to receipt of certain regulatory approvals, as well as other customary conditions. If the necessary approvals are not obtained within one year,
Vertex has signed a definitive agreement to purchase Crinetics Pharmaceuticals in a transaction valued at nearly $10bn, or $8.8bn net of estimated cash acquired.
Under the co-operative R&D agreement, BN ImmunoTherapeutics has rights to exclusively license intellectual property that results from this collaboration. Bavarian Nordic will in the future explore opportunities for